Novartis was announced as an official partner of this year’s Eurovision competition last fall, after the song entry from ...

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...

Swiss drugmaker Roche has abandoned global diverse workforce targets and compatriot Novartis is ending its use of diverse ...

Novartis Pharma Maroc has appointed Yahya Abdallah as country president for its Morocco, Tunisia, and Algeria (MTA) regional ...

An intravenous form of the gene therapy is already approved and sold as Zolgensma in the US for patients less than 2 years of age.

Basel: Novartis has announced that the U.S. Food and Drug Administration (FDA) has approved oral Fabhalta (iptacopan) for the ...

American football’s elite National Football League (NFL) has brought in US medicine company Novartis as the property's ...

Swiss pharmaceutical giants Roche and Novartis are revising their diversity policies in response to recent U.S. executive ...

Basel, March 20, 2025 - Novartis today announced that oral Fabhalta ® (iptacopan) has received U.S. Food and Drug Administration (FDA) approval for the treatment of adults with C3 glomerulopathy (C3G) ...